Verrica Pharmaceuticals Inc. Payments of Debt Restructuring Costs
Verrica Pharmaceuticals Inc. (VRCA) reported Payments of Debt Restructuring Costs of $110.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtRestructuringCosts · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for the quarter ending 2025-12-31 was $110.00K, a 10900.00% increase year-over-year.
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for fiscal 2025 was $110.00K, a 90.35% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for fiscal 2024 was $1.14M.
- Verrica Pharmaceuticals Inc. payments of debt restructuring costs for fiscal 2023 was $0.00.
| Period end | Payments of Debt Restructuring Costs 3 month | Payments of Debt Restructuring Costs 6 month | Payments of Debt Restructuring Costs 9 month | Payments of Debt Restructuring Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $110.00K derived: sum of 2 quarters · filed 2026-03-11 | $110.00K derived: sum of 3 quarters · filed 2026-03-11 | $110.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $1.00K derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $1.00K derived: sum of 3 quarters · filed 2026-03-11 | $18.00K derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $1.00K derived: sum of 2 quarters · filed 2026-03-11 | $18.00K derived: sum of 3 quarters · filed 2026-03-11 | $631.00K derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $18.00K derived: sum of 2 quarters · filed 2026-03-11 | $631.00K derived: sum of 3 quarters · filed 2026-03-11 | $1.14M 10-K · filed 2026-03-11 |
| 2024-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $630.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.14M 10-Q · filed 2025-11-14 | $1.14M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.12M 10-Q · filed 2025-08-12 | $1.12M derived: sum of 3 quarters · filed 2025-08-12 | $1.12M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $509.00K 10-Q · filed 2025-05-13 | $509.00K derived: sum of 2 quarters · filed 2025-05-13 | $509.00K derived: sum of 3 quarters · filed 2025-05-13 | $509.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |